Cervical Cancer Treatment Market Size, Share & Trends Analysis Report By Type (Squamous Cell Carcinomas, Adenocarcinomas, Adenosquamous Carcinomas), By Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Others), By End User (Hospitals, Cancer Care Centres, Research Institutes, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Market Overview

The global cervical cancer treatment market size was valued at 7.71 USD billion in 2022. It is projected to reach USD 11.76 billion by 2031, growing at a CAGR of 4.8% during the forecast period (2023–2031).

The body's unchecked cell proliferation brings on cervical cancer. Compared to the male population, it is much more common among women. Another critical factor anticipated to support the number of screening tests over the anticipated time frame is the existence of promising approaches identified with repayment. One form of cancer that affects the cells of the cervix is cervical cancer. The leading cause of cervical cancer in women is a variety of sexually transmitted infections, such as infection with the human papillomavirus. Doctors can diagnose different types of cervical cancer and learn about their treatment options thanks to early screening. The deeper tissues of the cervix may be affected by cervical cancer, which has the potential to spread to the lung, liver, bladder, vagina, and rectum.

One type of cancer that affects the cells of the cervix is cervical cancer. The primary cause of the rise in cervical cancer in women is a variety of physically transmitted infections, such as the human papillomavirus disease. The lower part of the uterus that joins the vagina is called the cervix. Modern cervical cancer symptoms include bleeding from the vagina, pelvic pain, and vaginal death. Cervical cancer is a severe health issue that affects women of average age worldwide.

Market Dynamics

Market Drivers

Pap-Test and Increased Use of HPV to Drive Cervical Cancer Treatment

According to statistics on cancer, women in low-resource and developing countries make up nearly 80% of cases of cervical cancer. In such economies as India, the inability to conduct cytology-based screening programs also significantly delays the diagnosis and treatment of cervical cancer. Medical experts believe a robust pre-screening protocol is crucial for identifying early cervical epithelial changes. The most common screening test for early-stage invasive cervical cancer and precancerous cervical intraepithelial neoplasia is still the Pap-Smear test. The National Breast and Cervical Cancer Early Detection Program (NBCCEDP), sponsored by the Centers for Disease Control and Prevention (CDC), assists low-income women who are both uninsured and insured in getting timely screenings.

Research & Development and Clinical Trials Gains Prominence

To determine whether cancer has spread, pelvic lymph nodes may be removed during surgery for cervical cancer. Sentinel lymph node biopsy allows for the selective removal of the few lymph nodes most likely to contain cancer as opposed to many lymph nodes. The rapid expansion of tumor cells is uncontrollable by the immune system. Immune checkpoint inhibitors are brand-new medications that "reset" the immune system. They have been found to work well in the treatment of various cancers. Vaccines are available to protect against some of the high-risk HPV strains linked to cervical cancer. Vaccines currently on the market are designed to create immunity to the HPV subtypes that account for 90% of cervical cancers.

Market Restraint

Lack Of Medical Professionals and A Weak Follow-Up System

Effective screening may also be hampered by the severe lack of healthcare professionals in developing nations. The total number of women in the province divided by 10 represents the annual number of women who need a Pap smear. Over ten years, each nurse would have to conduct, on average fewer than one Pap smear to reach 100% coverage of women eligible for screening. Poor follow-up and referral processes have been attributed to a lack of infrastructure and human resources. According to some studies, women with abnormal screening results were perplexed and did not comprehend the nurse's explanations.

Market Opportunities

Large-Scale Investments in The Infrastructure of The Health Care System

The modernization of healthcare infrastructure in developing nations is primarily funded by their governments, which is likely to increase access to healthcare. The demand for treatments for cervical cancer is anticipated to rise as a result. The global market for cervical cancer treatment has lucrative opportunities due to the rise in the prevalence of chronic heart diseases, particularly cervical cancer, in developing nations. By further developments, the US Food and Drug Administration (FDA) approved Keytruda, a drug developed by Merck that aims to provide a second-line option for the treatment of cervical cancer that is persistent, recurrent, and metastatic. TIL therapy demonstrated complete regression of cervical cancer that had spread to other organs in a study by the NIH.

Regional Analysis

The global cervical cancer treatment market is bifurcated into four regions: North America, Europe, Asia-Pacific, and LAMEA.

North America is the most significant shareholder in the global cervical cancer treatment market and is expected to grow at a CAGR of 4.9% during the forecast period. The U.S. and Canada are included in the analysis of the cervical cancer treatment market in North America. Due to significant businesses providing treatment for cervical cancer, technological developments, and an increase in the number of medical facilities. In North America, the prevalence of cervical cancer is increasing among females. This was attributed to rising disease prevalence, consumer awareness, and oncological disease diagnosis and treatment technology improvements. Positive lifestyle changes are expected to cause the regional market to grow even more. American Cancer Society stated that more than 14,000 new cases of cervical cancer would be identified, and the disease will likely claim the lives of 4000 women.

Europe is expected to grow at a CAGR of 5.7% during the forecast period. The UK, Germany, France, Italy, Spain, and the rest of Europe are all included in Europe's cervical cancer treatment market analysis. Due to technological advancements and the rising prevalence of cervical cancer in the continent, Europe commands a sizeable portion of the market for treatments for the disease. The favorable reimbursement environment and well-known regional international players contribute to the market's growth. The main drivers of the regional market are the adoption of better technologies, an increase in consumer awareness, and an increase in the number of health initiatives by private and public organizations. Because of the growing population, the prevalence of diseases, and the demand for affordable treatments, it is anticipated to grow steadily over the forecast period. The popularity of biosimilars in developing nations like China and India may change the region's therapeutic environment.

Segmental Analysis

The market is segmented by type, treatment, and end user.

Based on type, the global market is bifurcated into squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas.

The squamous cell carcinomas segment is the highest contributor to the market and is expected to grow at a CAGR of 5.6% during the forecast period. The most frequent type, representing more than 85% of all diagnosed cases, is squamous cell carcinoma (SCC). If left untreated, the cervix's High-Grade Squamous Intraepithelial Lesion (HSIL) may develop into SCC. Regular use of Pap tests for screening aids in the early identification and diagnosis of SCC. Women of certain racial groups, such as Hispanic and African-American women, are more likely to develop cervix adenocarcinoma. As seen under a microscope, histology distinguishes between SCC and adenocarcinoma. The least common type of adenosquamous carcinoma affects tissues that can be both squamous and glandular in the cervical region.

Based on treatment, the global market is bifurcated into surgery, radiation therapy, chemotherapy, targeted therapy, and others.

The surgery segment is the highest contributor to the market and is expected to grow at a CAGR of 5.0% during the forecast period. With a cone biopsy, removing a microscopic cervical cancer might be possible. The cervix is left intact after a cone-shaped section of cervical tissue is removed during this procedure. A radical hysterectomy removes the cervix, uterus, a portion of the vagina, and nearby lymph nodes and is used to treat most early-stage cervical cancers. Early-stage cervical cancer can be treated with a hysterectomy, stopping the recurrence. However, losing the uterus renders pregnancy impossible.

Based on end users, the global market is bifurcated into hospitals, cancer care centers, research institutes, and others.

The hospital segment is the highest contributor to the market and is expected to grow at a CAGR of 5.2% during the forecast period. In eastern, western, middle, and southern Africa, cervical cancer death is a common cause. These statistics are expected to increase the demand for cancer therapeutics during the forecast period. The disease of cervical cancer heavily burdens middle-aged women worldwide. Local hospitals are also a middle-class person's first point of contact for medical care. Cervical cancer can be beaten with the proper treatment from the right doctor at the right time, even though its detection is a cause for concern in and of itself.

Recent Developments

• September 2022, The US FDA will call a meeting of the Oncologic Drugs Advisory Committee to discuss overall survival data from the ENGOT-OV16/NOVA phase III clinical trial, according to a statement released by GSK plc today. NOVA is a phase III trial of Zejula (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, for women with platinum-sensitive recurrent ovarian cancer who receive maintenance therapy. It is a randomized, double-blind, placebo-controlled trial.
• September 2022, The first cervical cancer vaccine created in-house in India, CERVAVAC, is expected to cost between $200 and $400 per shot and be made commercially available. The Drug Controller General of India approved the Serum Institute of India's CERVAVAC in July.